Abstract
Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal (GI) disorder associated with abdominal pain and change in bowel habits that its etiology is not known yet. In the recent years, melatonin has been proposed as a possible candidate. In the present work, all clinical or non-clinical data about effects of melatonin in GI tract and IBS obtained from literature without time limit up to August 2010 have been studied and reviewed. Eight clinical trials were reviewed for the efficacy and disturbance of melatonin in IBS and other GI disorders. The results showed disturbances in endogenous melatonin concentration in IBS patients and significant benefits of exogenous melatonin in these patients by decreasing abdominal pain and improvement of overall IBS symptom scores. The results of seventeen non-clinical studies showed anxiolytic, anti-inflammatory, anti oxidative and motility regulatory effects of melatonin on GI tract. In conclusion, melatonin can be a target of interest in IBS because of its potentials to regulate GI motility.
Keywords: Irritable bowel syndrome, pharmaceutical management, treatment, melatonin, Melatonin Therapy, GI disorders, GI tract, central nervous system, anticholinergics, phosphodiesterase inhibitors, tricyclic antidepressants, 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, peppermint oil, Mellisa officinalis, Aloe vera, 5-methoxy-N-acetyl tryptamine, indolamine, L-tryptophan, N-acetyltransferas, hydroxyindole-O-methyl-transferase, diabetes, Parkinson's disease, colorectal cancer, ulcerative colitis, gastric ulcers, entrochromaffin cells, hydroxyindole-O methyltransferase, esophageal lesions, NF B, proinflammatory cytokines, tumor necrosis factor alpha, Antioxidant Effect, Effect on Prostaglandins, Hydrochloric Acid, Nitric Oxide, Serotonin, Nicotinic Receptors, Cholecystokinin
Current Pharmaceutical Design
Title: Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Volume: 16 Issue: 33
Author(s): Shilan Mozaffari, Roja Rahimi and Mohammad Abdollahi
Affiliation:
Keywords: Irritable bowel syndrome, pharmaceutical management, treatment, melatonin, Melatonin Therapy, GI disorders, GI tract, central nervous system, anticholinergics, phosphodiesterase inhibitors, tricyclic antidepressants, 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, peppermint oil, Mellisa officinalis, Aloe vera, 5-methoxy-N-acetyl tryptamine, indolamine, L-tryptophan, N-acetyltransferas, hydroxyindole-O-methyl-transferase, diabetes, Parkinson's disease, colorectal cancer, ulcerative colitis, gastric ulcers, entrochromaffin cells, hydroxyindole-O methyltransferase, esophageal lesions, NF B, proinflammatory cytokines, tumor necrosis factor alpha, Antioxidant Effect, Effect on Prostaglandins, Hydrochloric Acid, Nitric Oxide, Serotonin, Nicotinic Receptors, Cholecystokinin
Abstract: Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal (GI) disorder associated with abdominal pain and change in bowel habits that its etiology is not known yet. In the recent years, melatonin has been proposed as a possible candidate. In the present work, all clinical or non-clinical data about effects of melatonin in GI tract and IBS obtained from literature without time limit up to August 2010 have been studied and reviewed. Eight clinical trials were reviewed for the efficacy and disturbance of melatonin in IBS and other GI disorders. The results showed disturbances in endogenous melatonin concentration in IBS patients and significant benefits of exogenous melatonin in these patients by decreasing abdominal pain and improvement of overall IBS symptom scores. The results of seventeen non-clinical studies showed anxiolytic, anti-inflammatory, anti oxidative and motility regulatory effects of melatonin on GI tract. In conclusion, melatonin can be a target of interest in IBS because of its potentials to regulate GI motility.
Export Options
About this article
Cite this article as:
Mozaffari Shilan, Rahimi Roja and Abdollahi Mohammad, Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079254
DOI https://dx.doi.org/10.2174/138161210794079254 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Preliminarily Cytotoxicity to A549, HCT116 and MCF-7 Cell Lines of thieno[2,3-d]pyrimidine Derivatives Containing Isoxazole Moiety
Letters in Drug Design & Discovery Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin
Anti-Cancer Agents in Medicinal Chemistry Role of MicroRNA in the Diagnosis and Therapy of Hepatic Metastases from Colorectal Cancer
MicroRNA Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism A DNA Repair Pathway Polymorphism (rs25487) and Angiographically Proven Coronary Artery Patients in a Population of Southern Iran
Cardiovascular & Hematological Agents in Medicinal Chemistry Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Cellular and Physiological Effects of Arginine
Mini-Reviews in Medicinal Chemistry Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism
Recent Patents on Nanomedicine Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry HSV Amplicon Vectors for Cancer Therapy
Current Gene Therapy Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Bioactive Coumarins from Marine Sources: Origin, Structural Features and Pharmacological Properties
Current Topics in Medicinal Chemistry KRAS: A Promising Therapeutic Target for Cancer Treatment
Current Topics in Medicinal Chemistry Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets